Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Consolidated interim report' for the 6-month period ended 30 June 2025. It contains comprehensive financial statements, including the consolidated statement of comprehensive income, financial position, changes in equity, and cash flow statement, along with management's review and notes to the financial statements. This meets the criteria for an Interim/Quarterly Report (IR). H1 2025
2025-08-14 English
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document is an announcement of the H1-2025 interim report for Pharma Equity Group A/S. It provides a summary of key financial highlights, management changes, and strategic updates, and includes an invitation to an online presentation. Given the document length (3669 characters) and its function as a summary announcement of the financial results rather than the full comprehensive interim report itself, it falls under the category of an Earnings Release (ER), which covers initial announcements of periodic financial results.
2025-08-14 English
Regulatory Filings 2025
Regulatory Filings Classification · 96% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) dated May 28, 2025, detailing the launch of a new investment strategy, the diversification plans, and the establishment of a dedicated Investment Committee (IC). This type of announcement, which communicates significant strategic shifts, governance changes (like forming a new committee), and future outlook without being a full financial report (like 10-K or IR) or a specific transaction notice (like DIV or SHA), fits best under general regulatory announcements or governance updates. 1. It is not a full Annual Report (10-K) or Interim Report (IR). 2. It is not a Call Transcript (CT) or Earnings Release (ER). 3. It discusses changes in governance structure (Investment Committee) and strategy, which relates to Governance Information (CGR) or potentially Management Information (MANG). 4. Since the core message is the announcement of a new strategic direction and governance framework, CGR (Governance Information) is a strong candidate. However, the document is structured as a formal press release/company announcement regarding a major strategic shift, which often falls under general regulatory disclosures. 5. Given the focus on establishing a new committee to ensure 'Styrket governance' and the overall nature as a formal company announcement ('Selskabsmeddelelse nr. 7'), it strongly aligns with Governance Information (CGR). 6. It is not a short announcement merely pointing to another report, so RPA/RNS is less likely than CGR, which specifically covers internal rules and board structure/practices (the IC is a key governance mechanism). Conclusion: The document details a major strategic and governance overhaul, making CGR the most appropriate classification.
2025-05-28 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 98% confidence The document is an announcement dated May 28, 2025, titled "Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shareholder Returns." It details a strategic shift, the formation of an Investment Committee, and the expected benefits for shareholders. It is not a full annual report (10-K), an interim report (IR), or a formal earnings release (ER). It is an announcement regarding corporate strategy and governance changes, specifically mentioning the establishment of an Investment Committee, which relates to management and governance structure. However, the core content is a strategic announcement aimed at investors regarding future direction and value creation, which often falls under Investor Presentation (IP) or a general strategic update. Given the focus on launching a new strategy, governance structure (Investment Committee), and shareholder returns, it is a high-level strategic communication. Since there is no specific category for 'Strategy Launch,' and it is not a formal regulatory filing like a 10-K or a specific transaction report, it best fits as an Investor Presentation (IP) which often contains strategic roadmaps, or potentially a Regulatory Filing (RNS) if it were purely informational. Because it is a detailed strategic announcement intended for investors, IP is the most appropriate fit over the general RNS fallback. The document length is substantial (8159 chars), indicating it is the content itself, not just a brief announcement of an attachment (which would suggest RPA).
2025-05-28 English
Regulatory Filings 2025
Regulatory Filings Classification · 99% confidence The document is titled "Selskabsmeddelelse nr. 7" (Company Announcement No. 7) and dated May 28, 2025. It announces the launch of a new strategy, the establishment of an Investment Committee (IC), and changes in corporate structure, all aimed at accelerating growth and creating shareholder value. This type of announcement, which details strategic shifts, governance changes (like forming a committee), and future outlook, is typically classified as a general corporate update or regulatory filing. Since it is not a formal financial report (like 10-K or IR), an earnings release (ER), or a specific transaction notice (like DIV or POS), and it is a formal announcement, it fits best under the general regulatory announcement category, RNS, as it is a material event disclosure. However, the content heavily focuses on governance structure (Investment Committee) and strategic direction, which sometimes overlaps with Governance Information (CGR) or Management Reports (MDA). Given the context of a 'Company Announcement' detailing strategic direction and governance changes, RNS (Regulatory Filings) is the most appropriate catch-all for material, non-financial-statement disclosures, or it could be interpreted as a high-level Management Report (MDA) detailing future plans. Since it is a formal, numbered company announcement disclosing strategic and governance changes, RNS is the safest classification for a broad regulatory disclosure that isn't a specific financial report or insider trade. The document length (6591 chars) is substantial, suggesting it is the primary disclosure, not just a link announcement (RPA).
2025-05-28 Danish
Board/Management Information 2025
Board/Management Information Classification · 99% confidence The document is an official announcement dated May 28, 2025, detailing the launch of a new transformative investment strategy by Pharma Equity Group A/S. It discusses strategic direction, portfolio diversification (Pharma/MedTech), and the contemplated establishment of a dedicated Investment Committee (IC) to enhance governance. This type of announcement, focusing on strategic shifts, governance structure changes (like forming an IC), and future outlook, is characteristic of a high-level corporate update. It is not a formal regulatory filing like a 10-K or an IR, nor is it a transcript or a simple dividend notice. Since it details management's strategic explanation, outlook, and governance changes, it aligns best with the Management Reports (MDA) definition, which covers management's explanation of business trends and outlook, or potentially Governance Information (CGR). However, the primary focus is the *new strategy* and its execution framework (the IC), making MDA the most fitting category for a strategic business update from management.
2025-05-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.